Dai Nippon Printing completes acquisition of Kyowa Pharma Chemical
Dai Nippon Printing (DNP) has completed its acquisition of Kyowa Pharma Chemical, a Toyama-based active pharmaceutical ingredient maker, buying all shares from parent Kyowa Hakko Bio with effect from 1 October 2026. The deal follows a share purchase agreement signed on 15 July 2026. The target will be renamed DNP Pharma Chemical in February 2027 as DNP builds a one-stop contract development and manufacturing business spanning API production, formulation and pharmaceutical packaging.
Why this mattersDNP extends its pharmaceutical packaging and manufacturing base into API production, positioning itself as a one-stop CDMO for drugmakers.
- DNP completed acquisition of all shares of Kyowa Pharma Chemical on 1 October 2026
- Seller was Kyowa Hakko Bio, the target's previous parent
- Share purchase agreement was announced on 15 July 2026
- Kyowa Pharma Chemical will be renamed DNP Pharma Chemical in February 2027
- Kyowa Pharma Chemical is headquartered in Toyama Prefecture and makes active pharmaceutical ingredients
- DNP aims to combine the target's API technology with its own formulation and packaging manufacturing for end-to-end pharmaceutical CDMO services
Sources
Dai Nippon Printing Co., Ltd.
JA